Showing 4151-4160 of 5911 results for "".
- FDA Approves Regeneron's High-Dose Aflibercept, Eylea HDhttps://modernod.com/news/fda-approves-regenerons-high-dose-aflibercept-eylea-hd/2481782/In a major move that is expected to significantly extend dosing intervals for patients with retinal diseases, Regeneron received FDA approval for Eylea HD (aflibercept 8 mg) for patients with wet age-related macular degeneration (AMD), diabetic macular edema (DME) and diabetic reti
- Sandoz Announces Results from Mylight Phase 3 Study for Biosimilar Aflibercepthttps://modernod.com/news/sandoz-announces-results-from-mylight-phase-3-study-for-biosimilar-aflibercept/2481777/Sandoz released positive results from the MYLIGHT phase 3 confirmatory efficacy and safety study for its biosimilar aflibercept for wet macular degeneration (AMD). The Mylight phase 3 confirmatory efficacy and safety study (ClinicalTrials.gov NCT04864834) met its pri
- Lineage Cell Therapeutics Provides Update on OpRegenhttps://modernod.com/news/lineage-cell-therapeutics-provides-update-on-opregen/2481775/Lineage Cell Therapeutics provided an update on its progress with OpRegen (RG6501), its product candidate for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Lineage stated that it continues to execute its
- Rayner Completes First Implantations of IOLs in Clinical Trials in China and the UShttps://modernod.com/news/rayner-achieves-milestone-implantations-in-clinical-trials-in-china-and-the-us/2481774/Rayner has announced the completion of the first implantations in two pivotal market access studies in the US and China. Rayner's RayOne EMV Toric IOL received investigational device exemption (IDE) approval from the FDA in June. The first study implantation took place at
- Regeneron Presents 2-Year PULSAR Trial Results for Aflibercept 8 MG in Wet AMDhttps://modernod.com/news/regeneron-presents-2-year-pulsar-trial-results-for-aflibercept-8-mg-in-wet-amd/2481772/Regeneron announced positive, 2-year (96 weeks), topline data from the pivotal PULSAR trial investigating aflibercept 8 mg in patients with wet age-related macular degeneration (AMD). During the trial, aflibercept 8 mg patients were initially randomized to either 12- or 16-week dosing interv
- Oculis Announces that OCS-01, First Investigational Eye Drop for Front and Back of the Eye, Met Primary Endpoints in Phase 3 OPTIMIZE Trialhttps://modernod.com/news/oculis-announces-that-ocs-01-first-investigational-eye-drop-for-front-and-back-of-the-eye-met-primary-endpoints-in-phase-3-optimize-trial/2481769/Oculis announced positive topline results from its phase 3 OPTIMIZE trial with OCS-01 eye drops, a novel, once-daily, high concentration, preservative-free, topical Optireach formulation of dexamethasone for the treatment of inflammation and pain following ocular surgery. OPTI
- Haag-Streit to Host ‘Eyestar 900 Pearls of Cataract & Refractive Surgery with Swept-Source OCT’ Satellite Symposiumhttps://modernod.com/news/haag-streit-to-host-eyestar-900-pearls-of-cataract-refractive-surgery-with-swept-source-oct-satellite-symposium/2481767/Haag-Streit announced it will host the ‘Eyestar 900 Pearls of Cataract & Refractive Surgery with Swept-Source OCT’ Satellite Symposium at the 41st Congress of the ESCRS in September. Haag-Streit invites delegates to join its distinguished faculty for
- Iveric Bio Receives FDA Approval for Izervay for Geographic Atrophyhttps://modernod.com/news/iveric-bio-receives-fda-approval-for-izervay-for-geographic-atrophy/2481764/Iveric Bio has received FDA approval for Izervay (avacincaptad pegol intravitreal solution) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD), parent company Astellas Pharma announced Friday night. Izervay, a new complem
- Glaucoma Treatment Research at Missouri S&T Receives NIH Fundinghttps://modernod.com/news/glaucoma-treatment-research-at-missouri-st-receives-nih-funding/2481759/The Missouri University of Science and Technology (S&T) announced that the National Institutes for Health (NIH) has awarded an R01 grant to Professor Hu Yang, PhD, who is S&T’s Doshi Endowed Department Chair of Chemical and Biochemical Engineering. The grant will prov
- Skyline Therapeutics’ Gene Therapy Candidate for Wet AMD Receives IND Clearancehttps://modernod.com/news/skyline-therapeutics-gene-therapy-candidate-for-namd-receives-ind-clearance/2481758/Skyline Therapeutics announced that the FDA has cleared the company’s investigational new drug (IND) application for a phase 1/2a clinical trial of SKG0106, a one-time intravitreally delivered adeno-associated virus (AAV) gene therapy for the treatment of wet age-related macular degene